X-Linked Retinitis Pigmentosa (XLRP)
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Gene Therapy
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Beacon TherapeuticsMA - Cambridge
1 program1
Adeno-associated virus vector expressing a human RPGR genePhase 2Gene Therapy1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
Beacon TherapeuticsAdeno-associated virus vector expressing a human RPGR gene
Clinical Trials (1)
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Start: Sep 2025Est. completion: Dec 2030
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
1 companies competing in this space